The effects of rofecoxib, a cyclooxygenase (COX)-2 specific inhibitor, vs ibuprofen on biochemical indices of bone turnover in patients with osteoarthritis.

被引：0
|
作者：
Murphy, MG
Kivitz, AJ
Palmer, M
Zeng, Q
Bolognese, J
Gertz, BJ
机构：
[1] Merck Res Labs, Rahway, NJ USA
[2] Altoona Ctr Clin Res, Altoona, PA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 1999年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SA133
引用
收藏
页码：S342 / S342
页数：1
相关论文
共 33 条
  • [1] Effects of rofecoxib and ibuprofen on bone mineral density (BMD) and biochemical indices of bone turnover in patients with osteoarthritis
    Murphy, G
    DeTora, L
    Lee, M
    Gertz, B
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 264 - 264
  • [2] A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
    Day, R
    Morrison, B
    Luza, A
    Castaneda, O
    Strusberg, A
    Nahir, M
    Helgetveit, KB
    Kress, B
    Daniels, B
    Bolognese, J
    Krupa, D
    Seidenberg, B
    Ehrich, E
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (12) : 1781 - 1787
  • [3] A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis
    Laine, L
    Harper, S
    Simon, T
    Bath, R
    Johanson, J
    Schwartz, H
    Stern, S
    Quan, H
    Bolognese, J
    GASTROENTEROLOGY, 1999, 117 (04) : 776 - 783
  • [4] Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis.
    Hubbard, R
    Geis, GS
    Woods, E
    Yu, S
    Zhao, W
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S196 - S196
  • [5] Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
    Watson, DJ
    Harper, SE
    Zhao, PL
    Quan, H
    Bolognese, JA
    Simon, TJ
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (19) : 2998 - 3003
  • [6] Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis - A randomized, double-blind, placebo-controlled trial
    Hawkey, C
    Laine, L
    Simon, T
    Beaulieu, A
    Maldonado-Cocco, J
    Acevedo, E
    Shahane, A
    Quan, H
    Bolognese, J
    Mortensen, E
    ARTHRITIS AND RHEUMATISM, 2000, 43 (02): : 370 - 377
  • [7] A comparative study of platelet function in subjects receiving celecoxib, a COX-2 specific inhibitor, or ibuprofen. A nonspecific inhibitor of cyclooxygenase.
    Geis, GS
    FitzGerald, GA
    Karim, A
    Hubbard, RC
    Harper, K
    Yu, S
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S347 - S347
  • [8] Effect of the COX-2 specific inhibitor (C-2SI) rofecoxib on ulcer formation: A double-blind comparison with ibuprofen and placebo
    Laine, L
    Hawkey, C
    Harper, S
    Mortensen, E
    Beaulieu, A
    Qian, H
    Bolognese, J
    Simon, T
    GASTROENTEROLOGY, 1999, 116 (04) : A229 - A229
  • [9] Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
    Cannon, GW
    Caldwell, JR
    Holt, P
    McLean, B
    Seidenberg, B
    Bolognese, J
    Ehrich, E
    Mukhopadhyay, S
    Daniels, B
    ARTHRITIS AND RHEUMATISM, 2000, 43 (05): : 978 - 987
  • [10] Licofelone a 5-LOX, COX-1 and COX-2 inhibitor is as effective as naproxen and has improved GI tolerability in patients with osteoarthritis.
    Bias, P
    Buchner, A
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S72 - S72
1234